New president appointed at Nitto Denko Avecia Inc.

The global leader in oligonucleotide therapy development and manufacturing, Nitto Denko Avecia Inc. and Nitto Denko Avecia Pharma Services (Nitto Avecia), announced today that Tammy Cooper will be officially appointed as President of Nitto Avecia, effective June 21, 2024. Currently, Ms. Cooper serves as Vice President of Business Development and Project Management at Nitto Avecia. As President, she will report to Yoshihiko Terada, who will be appointed as Executive Chairman of Nitto Avecia. They will succeed the current company President, Seiji Fujioka, who will continue to serve as President during the transition period. Mr. Fujioka will remain as Executive Vice President of Nitto Denko after June 21, 2024, leading Nitto Denko's South Asia region, including India and Oceania.

Mr. Terada has worked at Nitto Denko for nine years, serving as Chief of Staff at Nitto Avecia and Corporate Vice President at Nitto Denko. Before joining Nitto Denko, Mr. Terada gained extensive experience in the pharmaceutical and management consulting industries.

Ms. Cooper has a strong background in the pharmaceutical field, beginning her career as a formulation chemist in small molecule manufacturing. She joined Nitto Avecia 19 years ago and has held increasingly diverse roles in marketing, business development, and project management. Most recently, she served as Vice President of Business Development and played a key role in Nitto Avecia's leadership team during the company's recent rapid growth phase.

Ms. Cooper said: "I am deeply honored to become Nitto Avecia's first female President. I am inspired by the limitless possibilities ahead for the company and the dedication, resilience, and commitment of our employees. With our culture of innovation, we will continue to drive the development and manufacturing of oligonucleotides to new heights of success."

Mr. Terada said: "The outlook for the oligonucleotide market is very optimistic, and Nitto Avecia and Nitto Avecia Pharma Services have tremendous opportunities to collaborate with customers to develop life-changing and life-saving drugs. I look forward to continuing to work with this exceptional team to contribute to patients and the oligonucleotide market."

Mr. Terada and Ms. Cooper will be based at Nitto Avecia's headquarters in Milford, Massachusetts.